

**Regd. Office :**  
'Zydus Tower'  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

<b>BSE Limited</b> 1 <sup>st</sup> Floor, P.J. Towers Dalal Street <u>Mumbai - 400 001</u>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, 5 <sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai - 400 051</u>
<b>Kind Attn.:</b> Mr. Sanjay Golecha / Mr. Gopalkrishnan	<b>Kind Attn.:</b> Famroze Pochara Asst. Vice President
<b>Date:</b> January 13, 2017	
<b>Re.:</b> Press Release	

Dear Sir / Madam,

We enclose herewith a copy of press release dated January 13, 2017, titled Zydus announces settlement with Upsher-Smith Laboratories, Inc. on Qudexy® XR (topiramate) extended-release capsules.

The contents of the press release give full details.


Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For, **Cadila Healthcare Limited**



**Upen H. Shah**  
Company Secretary



Encl.: As above

## **Zydus announces settlement with Upsher-Smith Laboratories, Inc. on Qudexy® XR (topiramate) extended-release capsules**

Ahmedabad, January 13, 2017

Cadila Healthcare Limited, a global pharmaceuticals company, and its subsidiary Zydus Pharmaceuticals (USA) Inc., a leading generic pharmaceutical company in the United States, today announced that they have finalized an agreement with Upsher-Smith Laboratories, Inc. to settle all outstanding patent litigation related to Qudexy® XR (topiramate) extended-release capsules.

Under the terms of the agreement, Upsher-Smith grants Zydus a license to market Zydus' generic version of Qudexy® XR beginning on March 19, 2020, or earlier under certain circumstances. Other terms of the settlement were not disclosed.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 19,500 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.